Patents by Inventor David Cladingboel

David Cladingboel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the preparation of oxabispidines
    Publication number: 20040133000
    Abstract: There is provided a process for the preparation of a benzenesulfonic acid salt of a compound of formula (1) which process comprises reaction of a compound of formula (II) with a compound of formula (III) wherein R1, R2, A and B have meanings given in the description.
    Type: Application
    Filed: October 10, 2003
    Publication date: July 8, 2004
    Inventors: Lal Cheema, David Cladingboel
  • Oxabispidine compound useful in the treatment of cardiac arrhythmias
    Publication number: 20040039199
    Abstract: There is provided 4-({3-[7-(3,3-dimethyl-2-oxobutyl)-9-oxa-3,7-diazabicyclo[3.3. 1]non-3-yl]propyl)}amino)benzonitrile, benzenesulfonic acid salt, which compound is useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
    Type: Application
    Filed: April 2, 2003
    Publication date: February 26, 2004
    Inventors: Magnus Bjorsne, David Cladingboel, Fritiof Ponten, Gert Strandlund
  • New oxabispidine compounds useful in the treatment of cardiac arrhythmias
    Publication number: 20030153564
    Abstract: There is provided compounds of formula I, 1
    Type: Application
    Filed: December 12, 2002
    Publication date: August 14, 2003
    Applicant: AstraZeneca AB
    Inventors: Annika Bjore, Magnus Bjorsne, David Cladingboel, Kurt-Jurgen Hoffmann, John Pavey, Fritiof Ponten, Gert Strandlund, Peder Svensson, Colin Thomson, Michael Wilsterman
  • Compounds
    Patent number: 6303659
    Abstract: The invention provides adamantane derivatives, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
    Type: Grant
    Filed: December 26, 2000
    Date of Patent: October 16, 2001
    Assignee: AstraZeneca AB
    Inventors: Andrew Baxter, Thomas McInally, Michael Mortimore, David Cladingboel
  • Pyridine derivatives and pharmaceutical compositions containing them
    Patent number: 6300352
    Abstract: The invention relates to novel pyridyl derivatives, their use as medicaments, pharmaceutical formulations containing them and methods for their preparation.
    Type: Grant
    Filed: May 11, 1998
    Date of Patent: October 9, 2001
    Assignee: AstraZeneca AB
    Inventors: David Cheshire, David Cladingboel, Simon Hirst, Carol Manners, Michael Stocks
  • Pyridine derivatives and pharmaceutical compositions containing them
    Patent number: 6265409
    Abstract: The invention relates to novel pyridyl derivatives, their use as medicaments, pharmaceutical formulations including them and methods for their preparation.
    Type: Grant
    Filed: May 11, 1998
    Date of Patent: July 24, 2001
    Assignee: AstraZeneca AB
    Inventors: David Cheshire, David Cladingboel, Simon Hirst, Carol Manners, Michael Stocks
  • Compounds
    Patent number: 6258838
    Abstract: The invention provides adamantane derivatives, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
    Type: Grant
    Filed: December 26, 2000
    Date of Patent: July 10, 2001
    Assignee: AstraZeneca AB
    Inventors: Andrew Baxter, Thomas McInally, Michael Mortimore, David Cladingboel
  • Adamantane derivatives
    Patent number: 6201024
    Abstract: The invention provides adamantane derivatives, a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy.
    Type: Grant
    Filed: January 26, 1999
    Date of Patent: March 13, 2001
    Assignee: AstraZeneca UK Limited
    Inventors: Andrew Baxter, Thomas McInally, Michael Mortimore, David Cladingboel
  • Compounds
    Patent number: 5977105
    Abstract: A compound of formula I, ##STR1## wherein--X represents (CH.sub.2).sub.n O, (CH.sub.2).sub.n S or C.sub.2 alkylene;n represents 1 or 2;Ar.sup.1 represents indanyl, tetrahydronaphthyl, naphthyl or phenyl, which latter two groups may be substituted by one or more substituents selected from chloro, fluoro, OR.sup.1, O(CH.sub.2).sub.m CONR.sup.20 R.sup.21, C(O)R.sup.2, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), pyridyl, thiazinyl, phenyl or C.sub.7-9 alkylphenyl which latter two groups are optionally substituted by one or more substituent selected from halo, nitro, OR.sup.3, C.sub.1-6 alkyl (optionally substituted by one or more fluorine atoms), C(O)R.sup.4, C(O)OR.sup.5, C(O)N(R.sup.6)R.sup.7, CN, CH.sub.2 OR.sup.14, CH.sub.2 NR.sup.15 R.sup.16, N(R.sup.8)R.sup.9, N(R.sup.10)SO.sub.2 R.sup.11, N(R.sup.12)C(O)R.sup.13, OC(O)R.sup.19 and SO.sub.2 NR.sup.17 R.sup.18 ;m represents an integer 1 to 3;R.sup.1, R.sup.2 and R.sup.3 independently represent H, C.sub.
    Type: Grant
    Filed: March 3, 1997
    Date of Patent: November 2, 1999
    Assignee: Astra Pharmaeuticals Ltd.
    Inventors: David Cheshire, David Cladingboel, David Hardern, Michael Stocks